Table 1. Parameters of oxidative stress in the liver, aorta and kidney cortex in SHR-CRP transgenic and wild-type controls treated with salsalate or placebo.
| Trait | SHR placebo | SHR salsalate | SHR-CRP placebo | SHR-CRP salsalate | P strain | P treatment | P interaction |
|---|---|---|---|---|---|---|---|
| Liver | |||||||
| SOD (U/mg) | 0.129±0.013 | 0.111±0.007 | 0.122±0.011 | 0.116±0.008 | NS | NS | NS |
| GSH-Px (μM NADPH/min/mg) | 275±18 | 287±17 | 190±18 | 230±16* | NS | NS | 0.002 |
| GR (μM NADPH/min/mg) | 250±20 | 306±30 | 303±22 | 224±21* | NS | NS | 0.005 |
| GSH (μM/mg prot.) | 43.2±4.5 | 41.3±2.7 | 39.2±3.5 | 39.6±2.1 | NS | NS | NS |
| CAT (mM H2O2/min/mg) | 1246±100 | 1747±173 | 1176±99 | 1520±100* | NS | NS | 0.039 |
| Conjugated dienes (nM/mg) | 35.3±2.7 | 35.7±3.4 | 33.6±2.6 | 31.6±3.9 | NS | NS | NS |
| TBARS (nM/mg) | 1.623±0.133 | 1.434±0.103 | 2.038±0.158 | 1.538±0.117* | NS | NS | 0.004 |
| Aorta | |||||||
| SOD (U/mg) | 0.156±0.018 | 0.186±0.028 | 0.131±0.014 | 0.190±0.016 | NS | 0.03 | NS |
| GSH-Px (μM NADPH/min/mg) | 46±4 | 63±3 | 30±5 | 46±4 | 0.001 | 0.001 | NS |
| GR (μM NADPH/min/mg) | 31±4 | 28±3 | 25±2 | 23±3 | NS | NS | NS |
| GSH (μM/mg prot.) | 2.682±0.308 | 2.242±0.264 | 2.764±0.562 | 2.183±0.253 | NS | NS | NS |
| CAT (mM H2O2/min/mg) | 143±15 | 214±17 | 180±19 | 243±23 | 0.01 | 0.002 | NS |
| Conjugated dienes (nM/mg) | 12.3±1.2 | 11.7±1.1 | 16.6±2.1 | 10.6±0.9* | NS | NS | 0.02 |
| TBARS (nM/mg) | 0.285±0.029 | 0.264±0.023 | 0.422±0.029 | 0.349±0.023 | 0.001 | NS | NS |
| Kidney cortex | |||||||
| SOD (U/mg) | 0.063±0.011 | 0.051±0.010 | 0.041±0.005 | 0.046±0.004 | NS | NS | NS |
| GSH-Px (μM NADPH/min/mg) | 150±15 | 246±15* | 108±8 | 146±10* | 0.001 | 0.001 | 0.03 |
| GR (μM NADPH/min/mg) | 34±3 | 48±5 | 36±2 | 42±5 | NS | 0.02 | NS |
| GSH (μM/mg prot.) | 15.2±1.5 | 17.3±1.7 | 19.2±1.5 | 19.6±1.1 | 0.048 | NS | NS |
| CAT (mM H2O2/min/mg) | 509±36 | 648±53 | 401±43 | 374±40 | 0.001 | NS | NS |
| Conjugated dienes (nM/mg) | 14.4±1.2 | 16.6±2.3 | 16.4±1.7 | 11.3±0.6* | NS | NS | 0.002 |
| TBARS (nM/mg) | 0.795±0.028 | 0.674±0.029 | 0.951±0.017 | 0.966±0.049 | 0.001 | NS | NS |
Two-way ANOVA results: “P interaction” denotes the significance of salsalate treatment x human CRP interaction (treatment x strain comparison)–salsalate treatment can protect against adverse effects that are dependent on human CRP. “P strain” denotes the significance of SHR-CRP vs. SHR controls (strain effects); “P treatment” denotes the significance of salsalate treatment vs. placebo (treatment effects). For comparisons versus controls, the Holm-Sidak test was used
* denotes P<0.05 significance of comparisons for salsalate vs. placebo treatment of nontransgenic SHR or transgenic SHR-CRP.
NS denotes not significant.